NervGen Pharma Corp. Common stock NGEN · Stock Open NervGen Pharma Corp. Common stock in new tab
NervGen Pharma Corp. Common stock Analysis (NGEN)
Is NervGen Pharma Corp. Common stock a good investment? NervGen Pharma Corp. Common stock (NGEN) is currently trading at 2.12 USD. Market analysts have a consensus price target of 11.21 USD. This suggests a potential upside from current levels.
Earnings Schedule: NervGen Pharma Corp. Common stock is expected to release its next earnings report on Aug. 12, 2026. The market consensus estimate for Forward EPS is -0.38.
Investor FAQ
Does NervGen Pharma Corp. Common stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is NervGen Pharma Corp. Common stock?
NervGen Pharma Corp. Common stock is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 12, 2026. The company currently has a trailing EPS of -0.45.
Company Profile
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Community Discussion